Article
RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese mice
2020-04-05
Abstract excerpt
<h4>ABSTRACT</h4> Tyrosine kinase inhibitors (TKIs) used in cancer are also being investigated in diabetes. TKIs can improve blood glucose control in diabetic cancer patients, but the specific kinases that alter blood glucose or insulin are not clear. We sought to define the role of Receptor Interacting Serine/Threonine Kinase 2 (RIPK2) in mouse models of insulin resistance. We tested the TKI gefitinib, which inh...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c4beada3-6590-5597-ae66-d29dac5e4907
- DOI
- 10.1101/2020.04.03.024620
